Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OTC vaginal antifungal products proposed class labeling announced July 16.

This article was originally published in The Tan Sheet

Executive Summary

FDA OTC VAGINAL ANTIFUNGAL PRODUCTS PROPOSED CLASS LABELING is intended to convey a "clear and consistent message" to the consumer, FDA explains in a draft guidance announced in the July 16 Federal Register. Current labeling for OTC vaginal yeast infection products "varies widely" among manufacturers, the draft notes, adding "in the OTC setting...consumers must have information that is easily understood to allow for appropriate self-selection and appropriate use of the product."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel